Wockhardt files fast – acting Insulin Aspart injection (ASPARAPID™) with DCGI; strengthens commitment to diabetes management
Wockhardt files fast – acting Insulin Aspart injection (ASPARAPID™) with DCGI; strengthens commitment to diabetes management
Wockhardt’s yet another novel antibiotic Miqnaf™ (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community – Acquired Bacterial Pneumonia (CABP)
Wockhardt’s yet another novel antibiotic MiqnafTM (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community – Acquired Bacterial Pneumonia (CABP)
Wockhardt’s another breakthrough antibiotic: once-a – day β – lactam enhancer, WCK 6777 with unique out – patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US
Wockhardt’s another breakthrough antibiotic: once – a – day β – lactam enhancer, WCK 6777 with unique out – patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US
